| Literature DB >> 25421141 |
Rana Jajou, Cornelia Christina Henrica Wielders, Monique Leclercq, Jeroen van Leuken, Shahan Shamelian, Nicole Renders, Wim van der Hoek, Peter Schneeberger.
Abstract
BACKGROUND: From 2007 to 2010, (the southern part of) the Netherlands experienced a large Q fever epidemic, with more than 4,000 reported symptomatic cases. Approximately 1 - 5% of the acute Q fever patients develop chronic Q fever. A high IgG antibody titre against phase I of Coxiella burnetii during follow-up is considered a marker of chronic Q fever. However, there is uncertainty about the significance and cause of persistence of high IgG phase I antibody titres in patients that do not have any additional manifestations of chronic Q fever. We studied whether continued or repeated exposure to the source of infection could explain elevated IgG phase I antibody levels.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25421141 PMCID: PMC4251683 DOI: 10.1186/s12879-014-0629-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Criteria for diagnosis of chronic Q fever, according to the Dutch Q fever consensus group [3]
| Classification | Definition |
|---|---|
|
| • Positive |
| • IFA phase I IgG titer ≥1:1,024 with definite endocarditis according to the revised Duke criteria* | |
| • IFA phase I IgG titer ≥1:1,024 with vascular infection diagnosed with PET/CT, CT, MRI or ultrasound testing | |
|
| IFA phase I IgG titer ≥1:1,024 with one of the following manifestations: |
| • Valvular deviation that does not meet the definition of endocarditis according to the Duke criteria | |
| • Aneurysm, valvular- or vascular prosthesis without an infection on PET/CT, CT, MRI or ultrasound testing | |
| • Suspicion of osteomyelitis or hepatitis as an expression of chronic Q fever | |
| • Pregnancy | |
| • Clinical symptoms of chronic infection (e.g. fever, weight loss, night sweating) | |
| • Granulomatous infection | |
| • Immunodeficiency | |
|
| Solely a phase I IgG ≥1:1,024¥, without any of the manifestations mentioned in the categories proven and probable. |
*A set of clinical criteria for the diagnosis of infective endocarditis.
¥Phase I IgG antibody titer ≥1:1,024 is within the JBZ measured between 9 - 18 months after acute Q fever diagnosis.
Figure 1Inclusion/exclusion criteria for patients without chronic Q fever and possible chronic Q fever patients. Legend: *JBH: Jeroen Bosch Hospital; BH: Bernhoven Hospital; PAMM: Laboratory for Pathology and Medical Microbiology.
Baseline characteristics of study population
| Possible chronic Q fever | Non chronic Q fever |
| |
|---|---|---|---|
| Gender (male) | 30 (56.6%) | 53 (48.2%) |
|
| Mean age ± SD | 56.3 (± 10.7) | 53.3 (± 12.1) |
|
| Living area (rural) | 36 (67.9%) | 65 (59.1%) |
|
| Participant of Q-HORT study | 21 (39.6%) | 110 (100%) |
|
| Year of acute Q fever diagnosis |
| ||
| 2007 | 4 (7.5%) | 24 (21.8%) | |
| 2008 | 16 (30.2%) | 41 (37.3%) | |
| 2009 | 22 (41.5%) | 45 (40.9%) | |
| 2010/2012 | 2 (3.8%) | 0 (0.0%) | |
| Unknown | 9 (17.0%) | 0 (0.0%) | |
| Hospitalization due to Q fever | 10 (18.9%) | 18 (16.4%) |
|
| Smoker | 11 (21.2%) | 38 (34.9%) |
|
| Co-morbidity | |||
| Cardiovascular disease | 0 (0%) | 7 (6.4%) |
|
| Immunosuppressed | 3 (5.7%) | 5 (4.5%) |
|
| Non-hematologic cancer | 4 (7.5%) | 3 (2.7%) |
|
| Pregnancy | 1 (1.9%) | 4 (3.6%) |
|
| Renal failure | 1 (2.0%) | 0 (0.0%) |
|
| Diabetes | 5 (9.4%) | 6 (5.5%) |
|
| Occupational risk | 2 (3.8%) | 3 (2.7%) |
|
| Contact animal products | |||
| Fertilizer | 8 (15.1%) | 9 (8.2%) |
|
| Hay and straw | 7 (13.2%) | 14 (12.7%) |
|
| Placental material | 4 (7.5%) | 1 (0.9%) |
|
| Fur/skin/wool | 30 (56.6%) | 63 (57.3%) |
|
| Intensity contact fertilizer |
| ||
| ≤3 times per week | 2 (3.8%) | 2 (1.8%) | |
| >3 times per week | 5 (9.6%) | 6 (5.5%) | |
| Intensity contact hay and straw |
| ||
| ≤3 times per week | 2 (3.8%) | 7 (6.4%) | |
| >3 times per week | 5 (9.4%) | 7 (6.4%) | |
| Intensity contact placental material |
| ||
| ≤3 times per week | 1 (1.9%) | 1 (0.9%) | |
| >3 times per week | 3 (5.7%) | 0 (0.0%) | |
| Intensity contact fur/skin/wool |
| ||
| ≤3 times per week | 1 (1.9%) | 7 (6.4%) | |
| >3 times per week | 29 (54.7%) | 55 (50.0%) | |
| Contact animals | |||
| Goats, cows or sheep | 5 (9.4%) | 6 (5.5%) |
|
| Cats | 13 (24.5%) | 19 (17.3%) |
|
| Dogs | 19 (35.8%) | 46 (41.8%) |
|
| Birds (including chicken and ducks) | 2 (3.8%) | 13 (11.8%) |
|
| Horses | 5 (9.4%) | 9 (8.2%) |
|
| Rodents | 3 (5.7%) | 7 (6.4%) |
|
| Others (rabbit, fish, pig, tortoise) | 2 (3.8%) | 10 (9.1%) |
|
| Intensity contact animals |
| ||
| ≤3 times per week | 2 (3.8%) | 6 (5.5%) | |
| >3 times per week | 28 (52.8%) | 59 (53.6%) | |
| Distance from house to infected farm |
| ||
| 0 - 2,000 m | 7 (13.2%) | 24 (22.0%) | |
| >2,000 - 5,000 m | 21 (39.6%) | 48 (44.0%) | |
| >5,000 m | 25 (47.2%) | 37 (33.9%) |
Univariate and multivariable analysis
| Univariate analysis | ||
|---|---|---|
| OR (95% CI) |
| |
| Age | 1.56 (0.81 - 3.01) |
|
| Gender | 0.71 (0.37 - 1.38) |
|
| Smoking | 0.50 (0.23 - 1.09) |
|
| Contact fertilizer | 2.00 (0.72 - 5.51) |
|
| Contact placental material | 8.90 (0.97 - 81.69) |
|
| Contact with birds | 0.29 (0.06 - 1.35) |
|
| Living distance to infected farm | ||
| <2,000 - 5,000 m | 1.50 (0.56 - 4.02) |
|
| >5,000 m | 2.32 (0.87 - 6.20) |
|
|
| ||
|
|
| |
| Smoking | 0.51 (0.23 - 1.13) |
|
| Contact placental material | 7.91 (0.85 - 73.99) |
|
| Contact with birds | 0.30 (0.07 - 1.41) |
|
Effect of living distance on the phase I and II IgG antibody titres
| Living distance from infected farm in meters, within case-control study † | phase I IgG <1:1,024 / ≥1:1,024 | phase II IgG <1:1,024 / ≥1:1,024 | ||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| >5,000 | ref* | ref* | ref* | ref* |
| >2,000 - 5,000 | 0.42 (0.16 - 1.11) |
| 0.59 (0.23 - 1.51) |
|
| 0 - 2,000 | 0.67 (0.33 - 1.36) |
| 1.00 (0.46- 2.18) |
|
|
|
|
| ||
|
|
|
|
| |
| >5,000 | ref* | ref* | ref* | ref* |
| >2,000 - 5,000 | 0.52 (0.28 - 0.93) |
| 0.98 (0.76 - 1.25) |
|
| 0 - 2,000 | 0.65 (0.41 - 1.03) |
| 0.98 (0.79 - 1.22) |
|
*ref = reference category.
†Case-control study exists of acute and possible chronic Q fever patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for Pathology and Medical Microbiology.
¥Q-HORT study exists of acute Q fever, possible, probable and proven chronic Q patients from the Jeroen Bosch Hospital, Bernhoven Hospital and Laboratory for Pathology and Medical Microbiology.
Serological follow-up of cases and controls
| Possible chronic Q fever | Possible chronic Q fever | ||||
|---|---|---|---|---|---|
| Antibody titers on the 24 thmonth after acute Q fever diagnosis | IgG phase I | IgG phase II | Antibody titers on the 36 thmonth after acute Q fever diagnosis | IgG phase I | IgG phase II |
| <1:32 | 0 (0.0%) | 0 (0.0%) | <1:32 | 0 (0.0%) | 0 (0.0%) |
| 1:32 - 1:128 | 2 (7.4%) | 0 (0.0%) | 1:32 - 1:128 | 1 (4.8%) | 0 (0.0%) |
| 1:256 - 1:512 | 7 (25.9%) | 2 (7.4%) | 1:256 - 1:512 | 7 (33.3%) | 3 (14.3%) |
| 1:1,024 - 1:2,048 | 12 (44.4%) | 13 (48.1%) | 1:1,024 - 1:2,048 | 10 (47.6%) | 12 (57.1%) |
| ≥1:4,096 | 6 (22.2%) | 12 (44.4%) | ≥1:4,096 | 3 (14.3%) | 6 (28.6%) |
|
|
| ||||
|
|
|
|
|
|
|
| <1:32 | 1 (2.9%) | 55 (51.0%) | <1:32 | 0 (0.0%) | 3 (2.8%) |
| 1:32 - 1:128 | 6 (17.6%) | 47 (43.9%) | 1:32 - 1:128 | 0 (0.0%) | 31 (29.0%) |
| 1:256 - 1:512 | 11 (32.4%) | 5 (4.7%) | 1:256 - 1:512 | 5 (14.7%) | 51 (47.7%) |
| 1:1,024 - 1:2,048 | 10 (29.4%) | 0 (0.0%) | 1:1,024 - 1:2,048 | 19 (55.9%) | 19 (17.8%) |
| ≥1:4,096 | 6 (17.6%) | 0 (0.0%) | ≥1:4,096 | 10 (29.4%) | 3 (2.8%) |
|
|
| ||||
*Chi-square test is used to calculate the p-value.
†There were three patients without chronic Q fever of which serological data of four years after acute Q fever diagnosis was missing.